Palvella Therapeutics, Inc. (PVLA)
- Previous Close
23.04 - Open
22.85 - Bid 22.32 x 100
- Ask 23.56 x 100
- Day's Range
22.31 - 23.39 - 52 Week Range
6.20 - 29.27 - Volume
17,410 - Avg. Volume
80,319 - Market Cap (intraday)
251.449M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-7.83 - Earnings Date May 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
49.33
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
palvellatx.comRecent News: PVLA
View MorePerformance Overview: PVLA
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PVLA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PVLA
View MoreValuation Measures
Market Cap
254.43M
Enterprise Value
170.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.06
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.40%
Return on Equity (ttm)
-59.37%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.43M
Diluted EPS (ttm)
-7.83
Balance Sheet and Cash Flow
Total Cash (mrq)
83.6M
Total Debt/Equity (mrq)
19.08%
Levered Free Cash Flow (ttm)
-5.43M